Go to the list of all blogs
Harry Richardson's Avatar
published in Blogs
Nov 18, 2026
TickeronGET DAILY SIGNALS
CDC ETF: VictoryShares US EQ Income Fund Eyes $85 Implied Target

CDC ETF: VictoryShares US EQ Income Fund Eyes $85 Implied Target

Key Takeaways

  • CDC is the VictoryShares US EQ Income Enhanced Volatility Wtd ETF, an income-focused fund tracking a volatility-weighted index of roughly 100 high-dividend large-cap U.S. stocks.
  • The $85 objective is drawn from public discussion—chiefly the weighted-average 12-month analyst price targets on CDC's underlying holdings (reported near $83–$85)—rather than a published consensus on the ETF itself.
  • With CDC trading around $76, reaching $85 implies an advance of roughly 11%, a modest move relative to normal market swings.
  • Implied targets on the underlying holdings span a wide range from about $70 to $96, reflecting genuine disagreement on how value, dividend, and financial-sector names will perform.
  • Supporting factors include a heavy tilt toward utilities and financials, a dividend yield near 3%, and a low-volatility weighting methodology.
  • Principal risks are interest-rate sensitivity, concentration in rate-sensitive sectors, and possible de-rating of defensive holdings.
  • For more detail on the fund's news, daily movement, outlook, and earnings, explore its Major News, Today's Price Move, Forecast, and Earnings pages.
  • Traders looking for additional AI-driven market tools can explore Trending AI Robots.

How the $85 Target Came About

As an exchange-traded fund, CDC does not receive direct analyst price targets the way an individual stock does. Instead, market commentators derive an implied objective from the 12-month price targets Wall Street assigns to the fund's underlying holdings. Because the index is volatility-weighted and roughly 100 names deep, no single stock dominates the result.

Independent aggregations of those underlying targets cluster in the mid-$80s. TipRanks reports an average 12-month price target of about $83, based on roughly 100 holdings, with a low near $70 and a high near $96. Another public projection, computed by weighting individual analyst targets by each holding's index weight, points to roughly $85 over the next 12 months. The $85 figure used here is therefore a rounded, publicly discussed price objective—not an official consensus, and not a forecast issued on the ETF itself. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Ratings on the underlying basket lean constructive, with a large majority of Buy ratings relative to Hold and Sell ratings, but the unusually wide $70-to-$96 range signals that analysts disagree sharply about the outlook for the fund's dominant sectors.

Current Market Position and Path Toward the Target

The fund has traded in a broad 52-week range from roughly $64 to around $78, and recent quotes near $76 leave it in the upper portion of that range. From about $76, a move to $85 represents upside of roughly 11%—a modest step that is larger than a routine daily swing but well within what the fund has delivered over the past year.

The path to $85 would most likely require continued strength across the fund's largest exposures. Financial services and utilities together account for nearly half of the portfolio, with consumer staples adding another sizable slice. Top holdings include LNT, WEC, EVRG, DUK, and DTE, alongside familiar staples names such as KO and SO. A broad advance in dividend-paying, defensive large caps would be the most direct route to the target.

What Could Support a Move Toward the Target

Several structural features could underpin gains. The fund's volatility-weighting methodology tilts toward steadier, income-generating companies, which can attract investors seeking lower drawdowns. A dividend yield near 3% and a price-to-earnings (P/E) ratio in the mid-teens give the portfolio an income and valuation profile that can appeal during uncertain markets. Utilities and staples historically benefit when investors rotate toward defense, while financials can gain when credit conditions stay healthy and rates are stable. Favorable earnings revisions among large holdings, steady dividend growth, and continued fund inflows would all reinforce the case for higher prices.

What Could Prevent the Target From Being Reached

The fund's concentration in rate-sensitive sectors is a double-edged sword. Utilities and high-dividend stocks often behave like bond proxies, and rising long-term interest rates can pressure their valuations even if earnings are stable. A rotation back into growth or technology could leave this income-oriented basket lagging, and any weakness in the banking and insurance names within the financials sleeve would weigh on performance. Slower dividend growth, guidance cuts among major holdings, or a broader valuation de-rating of defensive large caps would each make $85 harder to reach.

Technical Levels and Market Structure

The fund's prior 52-week high near $78 stands as the first meaningful resistance level; a sustained close above that area would open the path toward the psychologically significant $80 mark and then the $85 objective. On the downside, recent consolidation around $72–$73 and the longer-term moving averages near $69 provide support. The fund remains in a longer-term uptrend, but the distance between current prices and the $85 target means the move would require a decisive break above recent highs rather than a simple continuation of sideways trading.

Time Horizon and What Investors Should Monitor

Because the $85 objective is derived from analyst price targets on the underlying holdings, it carries an implicit research horizon of roughly 12 months. Investors should monitor quarterly earnings and dividend announcements from the fund's largest utility, financial, and staples holdings, as revisions to those companies' targets directly influence the implied fund objective. Interest-rate decisions, Treasury yields, sector rotation trends, and monthly fund flows are also key variables. ETF-specific updates—such as changes in holdings weightings or the index methodology—can shift the outlook as well.

AI Daily Buy/Sell Signals

Tickeron's AI Daily Buy/Sell Signals apply artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on evolving market conditions, technical behavior, and AI-driven analysis. Rather than relying on static rules, the system updates as price action and market structure shift, helping traders surface opportunities, monitor existing positions, and spot changing trends more efficiently. For those tracking CDC's progress toward its $85 objective, these signals offer a complementary, data-driven lens on momentum and turning points.

Using Tickeron AI Tools in My Analysis

In my own work, I often turn to Tickeron’s AI Trading Bots to test how different scenarios might play out for holdings like those in CDC. The platform lets me run virtual trades and see how the portfolio could respond to shifts in rates or sector rotation, giving me a clearer sense of risk and reward before committing capital. It has become a regular part of reviewing defensive income strategies like this one.

Final Assessment

The question of whether CDC can reach $85 hinges less on a single catalyst and more on the broad behavior of its defensive, income-oriented holdings. The objective, drawn from publicly discussed analyst targets on the underlying stocks, implies a modest advance of roughly 11% from current levels. Support comes from the fund's low-volatility design, income generation, and value-oriented sector mix, while the principal obstacles are interest-rate sensitivity and the risk that defensive names de-rate or lag a growth-led rally. The unusually wide $70-to-$96 range in underlying targets underscores how much analyst opinion diverges. Investors should weigh these factors against their own objectives and watch earnings, rate moves, and fund flows rather than treating any single price level as a foregone conclusion.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CDC

Contributor

Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.


CDC's RSI Indicator recovers from overbought zone

The 10-day RSI Oscillator for CDC moved out of overbought territory on November 05, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 instances where the indicator moved out of the overbought zone. In 27 of the 31 cases the stock moved lower in the days that followed. This puts the odds of a move down at 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 66 cases where CDC's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 65%.

The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CDC as a result. In 51 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 57%.

The Moving Average Convergence Divergence Histogram (MACD) for CDC turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 54 similar instances when the indicator turned negative. In 33 of the 54 cases the stock turned lower in the days that followed. This puts the odds of success at 61%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CDC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.

CDC broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

CDC moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for CDC crossed bullishly above the 50-day moving average on October 23, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 71%.

Following a +0.44% 3-day Advance, the price is estimated to grow further. Considering data from situations where CDC advanced for three days, in 268 of 346 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.

The Aroon Indicator entered an Uptrend today. In 279 of 364 cases where CDC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 77%.

Notable companies

The most notable companies in this group are Southern Company (The) (NYSE:SO).

Industry description

The investment seeks to provide investment results that track the performance of the Nasdaq Victory U.S. Large Cap High Dividend 100 Long/Cash Volatility Weighted Index before fees and expenses. The fund seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its assets directly or indirectly in the securities included in the Nasdaq Victory U.S. Large Cap 100 High Dividend Long/Cash Volatility Weighted Index. The index identifies the 100 highest dividend yielding stocks in the Nasdaq Victory U.S. Large Cap 500 Volatility Weighted Index.

Market Cap

The average market capitalization across the VictoryShares US EQ Income Enhanced Volatility Wtd ETF (CDC) ETF is 91.77B. The market cap for tickers in the group ranges from 18.84B to 106.22B. SO holds the highest valuation in this group at 106.22B. The lowest valued company is LNT at 18.84B.

High and low price notable news

The average weekly price growth across all stocks in the VictoryShares US EQ Income Enhanced Volatility Wtd ETF (CDC) ETF was 9%. For the same ETF, the average monthly price growth was 29%, and the average quarterly price growth was 67%. DUK experienced the highest price growth at 2%, while LNT experienced the biggest fall at -3%.

Volume

The average weekly volume growth across all stocks in the VictoryShares US EQ Income Enhanced Volatility Wtd ETF (CDC) ETF was 12%. For the same stocks of the ETF, the average monthly volume growth was -9% and the average quarterly volume growth was -3%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 66
P/E Growth Rating: 46
Price Growth Rating: 39
SMR Rating: 52
Profit Risk Rating: 56
Seasonality Score: 17 (-100 ... +100)
AI Screener 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SAP's U.S. shares fell from Monday's close of $233.83 to $221.99 by late Tuesday morning in New York, a -5.06% decline recorded during regular trading hours. The company-specific trigger was the announced exit of Chief Customer Officer Thomas Saueressig, an executive board member since 2019, who will leave at the end of March 2027 to become CEO of IONOS; the disclosure came before the U.S. open.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
IonQ slid from Monday's close of $26.45 to $24.73 on Tuesday, a -6.50% move that unfolded during regular trading hours after modest premarket gains faded. The decline was sector-driven rather than company-specific: quantum and AI-adjacent speculative names extended a multi-session liquidation ahead of Nvidia's quarterly report, with unease over Nvidia's abrupt CEO transition keeping risk appetite weak.